Clinical Report: In Vitro Analysis of FGF, PDGF, VEGF, and GM-CSF Production

Overview

This study investigates the in vitro secretion of pro-angiogenic factors by PBMCs from women with and without endometriosis. Findings indicate no significant differences in baseline or stimulated growth factor levels between the two groups, suggesting a localized rather than systemic dysregulation in endometriosis.

Background

Endometriosis is a prevalent chronic inflammatory condition affecting a significant proportion of women of reproductive age, characterized by the presence of endometrial-like tissue outside the uterus. Understanding the role of immune dysregulation and growth factor secretion in endometriosis is crucial for developing targeted therapies, as current treatments primarily provide symptomatic relief without addressing underlying mechanisms.

Data Highlights

No significant differences in baseline secretion of FGF, PDGF, VEGF, and GM-CSF between women with endometriosis and controls were observed. PHA stimulation resulted in increased secretion of FGF, PDGF, and VEGF, but these changes were not significantly different between groups.

Key Findings

• Baseline secretion of FGF, PDGF, VEGF, and GM-CSF did not differ significantly between women with endometriosis and controls.
• PHA stimulation led to increased secretion of FGF, PDGF, and VEGF, with a decrease in GM-CSF.
• Neither stimulated concentrations nor percent changes in growth factors differed significantly between groups after multiple testing correction.
• Univariate logistic regression analyses showed no baseline growth-factor measures predicted endometriosis status.
• The findings suggest a compartmentalized model of pro-angiogenic signaling in endometriosis rather than systemic hypersecretion.

Clinical Implications

The results indicate that PBMCs from women with endometriosis do not exhibit a generalized increase in pro-angiogenic growth factor secretion, which may influence treatment strategies. Clinicians should consider the localized nature of angiogenic signaling in endometriosis when developing therapeutic approaches.

Conclusion

This study provides evidence that PBMCs from women with endometriosis do not demonstrate systemic hypersecretion of key pro-angiogenic factors, emphasizing the importance of local microenvironments in disease pathology.

Related Resources & Content

1. Frontiers, Source, 2026 -- PBMC-derived FGF, PDGF, VEGF and GM-CSF secretion in endometriosis: a case–control in vitro study
2. The Journal of Clinical Endocrinology & Metabolism, Source, 2024 -- Investigating the Function of SAA1 in Endometrial ECM Remodeling Associated with Polycystic Ovary Syndrome: Consequences for Pregnancy Outcomes
3. the pathologist, Source, 2026 -- Endometriosis Blood Test: An End to Years of Agony?
4. Archives of Toxicology, Source, 2024 -- Environmental Levels of Bisphenol Z Disrupt Mitochondrial Function and Growth Potential in Human Ovarian Granulosa Cells by Altering Metabolic Substrate Use
5. Diagnosis of Endometriosis | ACOG, Source, 2026 -- Diagnosis of Endometriosis
6. The Journal of Clinical Endocrinology & Metabolism — Modulating Premenstrual Levels of Endometrial Hypoxia Inducible Factor 2 Alpha May Enhance Endometrial Function During Menstruation
7. Diagnosis of Endometriosis | ACOG
8. JCI Insight - Neutrophils initiate proinflammatory immune responses in early endometriosis lesion development
9. Frontiers | PBMC-derived FGF, PDGF, VEGF and GM-CSF secretion in endometriosis: a case– control in vitro study